December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Anirban Maitra: Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC) led by Eileen M O’Reilly
Oct 29, 2024, 09:39

Anirban Maitra: Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC) led by Eileen M O’Reilly

Anirban MaitraProfessor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X:

An important single institution study led by Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in Journal of the National Cancer Institute (JNCI).”

Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.

With all the caveats of a retrospective single center study, and limitations of small genetic subsets (like only a few HRD patients that may explain the absence of correlation with improved response), this is still an important demonstration for WHY earlier detection, successful surgery and timely administration of adjuvant therapy (even with reduced doses) is SO pivotal to longer survival.

OS stratified by age below.”

Anirban Maitra

 

Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort

Authors: Fergus Keane, Catherine O’Connor, Drew Moss, Joanne F Chou, Maria A Perry, Fionnuala Crowley, Parima Saxena, Amelia Chan, Joshua D Schoenfeld, Anupriya Singhal, Wungki Park, Darren Cowzer, Emily Harrold, Anna M Varghese, Imane El Dika, Christopher Crane, James J Harding, Ghassan K Abou-Alfa, T Peter Kingham, Alice C Wei, Kenneth H Yu, Michael I D’Angelica, Vinod P Balachandran, Jeffrey Drebin, William R Jarnagin, Chaitanya Bandlamudi, David Kelsen, Marinela Capanu, Kevin C Soares, Fiyinfolu Balogun and Eileen M O’Reilly.

Anirban Maitra: Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC) led by Eileen M O’Reilly

Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.